Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 4 boards, counting each seat separately. Longest: Natera Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Travere Therapeutics Inc. May 19, 202687.7%
-
Natera Inc. June 12, 202580.9%
-
Nurix Therapeutics Inc. May 19, 202599.3%
-
Travere Therapeutics Inc. May 15, 202599.0%
-
Travere Therapeutics Inc. May 8, 202495.4%
-
Travere Therapeutics Inc. May 17, 202394.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 26, 2026 | Natera Inc. | Grant or award | +1,571 | — | — |
| Jun 26, 2026 | Natera Inc. | Grant or award | +75 | — | — |
| Jun 12, 2026 | Travere Therapeutics Inc. | Option exercise | +4,500 | $21.38 | $96,210 |
| Jun 12, 2026 | Travere Therapeutics Inc. | Open-market sale | −4,500 | $50.00 | $225,000 |
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| May 5, 2026 | Travere Therapeutics Inc. | Option exercise | +4,500 | $18.27 | $82,215 |
| May 5, 2026 | Travere Therapeutics Inc. | Open-market sale | −4,500 | $46.65 | $209,925 |
| May 1, 2026 | Travere Therapeutics Inc. | Option exercise | +9,750 | $6.82 | $66,495 |
| May 1, 2026 | Travere Therapeutics Inc. | Open-market sale | −9,750 | $44.22 | $431,145 |
| Apr 24, 2026 | Natera Inc. | Grant or award | +83 | — | — |
| Apr 14, 2026 | Travere Therapeutics Inc. | Option exercise | +8,000 | $17.94 | $143,520 |
| Apr 14, 2026 | Travere Therapeutics Inc. | Option exercise | +9,000 | $15.43 | $138,870 |
| Apr 14, 2026 | Travere Therapeutics Inc. | Option exercise | +4,500 | $18.27 | $82,215 |
| Apr 14, 2026 | Travere Therapeutics Inc. | Option exercise | +4,500 | $21.38 | $96,210 |
| Apr 14, 2026 | Travere Therapeutics Inc. | Option exercise | +6,750 | $17.11 | $115,493 |
Questions about Roy D. Baynes
What boards is Roy D. Baynes on?
Roy D. Baynes sits on the boards of Aardvark Therapeutics Inc., Natera Inc., Nurix Therapeutics Inc. and Travere Therapeutics Inc.
How long has Roy D. Baynes served on boards?
Our records show at least 11 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.